Mr. Luc Bonnefoy reports

BAUSCH + LOMB ANNOUNCES EUROPEAN CE MARK APPROVAL OF SEELYRA FEMTOSECOND LASER

Bausch + Lomb Corp. has received European CE Mark approval of SeeLyra, the company's next-generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, Lasik flap and corneal therapeutic surgeries while simultaneously supporting the fast, efficient workflows needed in modern operating rooms (ORs).

"Building on over 15 years of experience in the femtocataract laser market, our goal was to deliver a platform that provides both enhanced functionality and greater flexibility to the OR," said Luc Bonnefoy, president, surgical, Bausch + Lomb. "SeeLyra delivers, helping surgeons achieve the precise preparation and controlled conditions necessary to unlock the full potential of premium cataract surgery without compromising on space or efficiency."

SeeLyra features integrated tools that provide accuracy and control. Live swept-source OCT (optical coherence tomography) provides real-time depth visualization throughout the procedure, helping to reduce variability during docking while enabling precise positioning of laser cuts and visual control during laser application. SeeLyra also retains vital, highly appreciated features of Victus, the previous-generation Bausch + Lomb femtosecond platform, such as an intuitive user interface designed to streamline set-up and adaptability for a wide range of procedures including cataract, Lasik flap and corneal therapeutic treatments.

Compact design, the absence of a fixed patient bed as well as compatibility with existing bed set-ups allow for the flexible positioning and easy transport of SeeLyra across modern, space-constrained OR environments. The absence of a fixed bed also contributes to patient comfort, eliminating the need to switch beds between procedures. An articulating swing arm accommodates surgeons' preferred orientation for performing surgery.

"Premium surgery success begins with precise surgical preparation of the eye," said Dr. Jose Manuel Larrosa, MD, University of Zaragoza, Spain. "SeeLyra will help me to achieve this consistently on my terms, while fitting seamlessly and efficiently into our OR space and workflow."

SeeLyra will be available in Europe on a limited basis in the coming months, with increasing availability expected in 2027. Bausch + Lomb is also in the process of seeking regulatory approvals for SeeLyra in markets around the world, including the United States. Indications and approvals may vary by country.

About Bausch + Lomb Corp.

Bausch + Lomb's mission is simple -- the company helps people see better to live better, all over the world. For nearly two centuries, Bausch + Lomb has evolved with the changing needs of patients and customers, and the company's commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, Bausch + Lomb is turning bold ideas into better outcomes through passion, perseverance and purpose.